learn PP405
mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials
Search
forLearn
1 / 1 resultsResearch
5 / 798 resultsresearch Defolliculated (Dfl): A Dominant Mouse Mutation Leading to Poor Sebaceous Gland Differentiation and Total Elimination of Pelage Follicles
The Dfl mutation in mice causes poor sebaceous gland function and complete hair loss.
research Immunohistochemical and Autoradiographic Findings Suggest Minoxidil Is Not Localized in Specific Cells of Vibrissa, Pelage, or Scalp Follicles
Minoxidil does not specifically target any hair follicle cells.
research Ficoll Density Gradient Sedimentation Isolation of Pelage Hair Follicle Mesenchymal Stem Cells From Adult Mouse Back Skin: A Novel Method for Hair Follicle Mesenchymal Stem Cells Isolation
A new method quickly and efficiently isolates hair follicle stem cells from adult mice, promoting hair growth.
research Ficoll Density Gradient Sedimentation Isolation of Pelage Hair Follicle Mesenchymal Stem Cells from Adult Mouse Back Skin: A Novel Method for Hair Follicle Mesenchymal Stem Cells Isolation
The new method isolates more hair follicle stem cells from mice quickly and these cells help promote hair growth.
research Control of Pelage Hair Follicle Development and Cycling by Complex Interactions Between Follistatin and Activin
Follistatin helps hair growth and cycling, while activin prevents it.
Community Join
5 / 152 resultscommunity New Study: PP405, developed by Pelage Pharmaceuticals, can reactivate dormant hair follicle stem cells and stimulate natural hair growth by 20%
PP405, developed by Pelage Pharmaceuticals, can reactivate dormant hair follicle stem cells and increase hair growth by 20% in eight weeks, unlike minoxidil or finasteride. However, skepticism remains about its effectiveness and availability, with concerns about funding and the timeline for broader access.
community Anyone here have a lot of knowledge on hair follicle stem cells and progenitor cells for PP405?
Hair follicle stem cells remain in bald individuals, but progenitor cells do not, raising questions about hair regrowth claims by Pelage. PP405 is discussed as a potential treatment, with skepticism about its effectiveness compared to existing treatments like Minoxidil and Finasteride.
community Quote from Pelage (PP-405) Spokesperson...
Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.
community Pelage Pharmaceuticals’ PP405 and its Impact on Follicular Regeneration to be Presented at the American Academy of Dermatology (AAD) Annual Meeting 2026 28th march
Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.
community Pelage, PP405, is creating a database for potential new trial volunteers
PP405 is a new hair loss treatment targeting dormant hair follicles, with ongoing trials. Some users consider stopping finasteride and minoxidil to join trials, while others doubt its effectiveness.